MFDS
- Status: likely_approved
🇰🇷 Augtyro in South Korea
Augtyro (REPOTRECTINIB) regulatory status in South Korea.
Marketing authorisation
Augtyro in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is Augtyro approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Augtyro in South Korea?
Bristol is the originator. The local marketing authorisation holder may differ — check the official source linked above.